|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
Recent Developments in the Treatment of Clear Cell, Renal Cell Carcinoma: Essential Insights and Updates for the Healthcare Team
Target Audience
Oncology, Managed care and Specialty Pharmacists and Oncology Nurses/Nurse Practitioners
Program Overview
The goal of this educational initiative is to equip oncology nurse practitioners and nurses, as well as oncology, managed care, and specialty care pharmacists with the knowledge to apply findings from risk scoring systems used to stratify cases of clear cell renal cell carcinoma for treatment selection, differentiate among an expanding array of combination regimens con... |
|
Comprehensive Management of Von Hippel-Lindau Disease: Genetic and Oncological Perspectives
STATEMENT OF NEED
Von Hippel-Lindau disease (VHL) is an autosomal dominant disease in which germline pathogenic variants in the VHL gene predispose individuals to specific types of benign tumors, malignant tumors, and cysts in multiple organs, including clear cell renal cell carcinoma (RCC), renal cysts, central nervous system hemangioblastomas, retinal hemangioblastomas, pancreatic tumors and cysts, endolymphatic sac tumors, and cystadenomas of the epididymis and broad ligament (NIH, 2024). ... |
|
Establishing Frameworks for Precision Medicine in NTRK Fusion-Positive Advanced Solid Tumors
Despite significant advancements over the past decade, significant unmet needs persist for patients with NTRK-positive locally advanced or metastatic solid tumors. In addition, there is ongoing debate about the importance of testing for genomic alterations in rare cancers, or those that rarely occur in common cancers. However, evolving molecular testing procedures and emerging therapeutic options targeting NTRK fusions offer new pathways for the detection and treatment of these cancers. To he... |
|
Advances in Recurrent/Metastatic Nasopharyngeal Carcinoma: Immunotherapy and Biomarkers
Target Audience
This activity was developed for medical oncologists, head and neck surgeons, radiation oncologists, physician associates, nurse practitioners, nurses and pharmacists involved in the care of patients diagnosed with metastatic nasopharyngeal carcinoma (NPC).
Program Overview
Greater understanding of the tumor microenvironment of nasopharyngeal carcinoma (NPC) has led to the introduction of immunotherapy into the NPC treatment landscape. Incorporating immunotherapy has change... |
|
Toxicity Management and Symptom Control in Advanced RCC: Playbook Update
STATEMENT OF NEED
Each year, more than 430,000 cases of kidney cancer are diagnosed worldwide. Renal cell carcinoma (RCC), which includes clear cell, papillary, and chromophobe subtypes, is the most common form of kidney cancer. In recent years, the rise of immunotherapy and targeted therapy has contributed to a revolution in the treatment of RCC, with several novel agents and combinations granted approval. While these treatments demonstrate superior efficacy compared with previous standard... |
|
Cleveland Clinic Multispecialty Pathology Symposium (online streaming & flash drive formats)
The Cleveland Clinic Multispecialty Pathology Symposium features an expert faculty addressing commonly encountered problems and providing practical tips from their own experience at the microscope. A broad spectrum of cases will be presented, reviewing genitourinary, pulmonary, gastrointestinal and soft tissue, gynecologic, and breast pathology. Participation in this activity will increase knowledge and improve performance in pathology, which will positively impact patient care.
Worth 16.... |
|
Nursing Management of Oral Mucositis
STATEMENT OF NEED
Oral mucositis (OM) is the inflammation of oral mucosa resulting from cancer therapy and manifesting as atrophy, swelling, erythema, and ulceration (Oronsky et al, 2018). Patients with OM may experience moderate-to-severe pain, difficulty speaking, difficulty eating and drinking, and ulcerations characterized by submucosal hemorrhaging and infection (Bolton, 2021). Due to these crippling effects, OM is considered one of the most debilitating toxicities of cancer therapy (W... |